Chmait RH, Chavira E, Kontopoulos EV, Quintero RA Third trimester fetoscopic laser ablation of type II vasa previa. J Matern Fetal Neonatal Med. 2010 May;23(5):459-62. doi: 10.1080/14767050903156718.
Chmait RH, Kontopoulos EV, Chon AH, Korst LM, Llanes A, Quintero RA Amniopatch treatment of iatrogenic preterm premature rupture of membranes (iPPROM) after fetoscopic laser surgery for twin-twin transfusion syndrome. J Matern Fetal Neonatal Med. 2017 Jun;30(11):1349-1354. doi: 10.1080/14767058.2016.1214123. Epub 2016 Aug 10.
Dindo D, Demartines N, Clavien PA Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13. doi: 10.1097/01.sla.0000133083.54934.ae.
Green A, Chiu S, Manor E, Smith L, Oyelese Y The association of gestational age at delivery with neonatal outcomes in prenatally diagnosed vasa previa. J Matern Fetal Neonatal Med. 2022 Dec;35(25):10162-10167. doi: 10.1080/14767058.2022.2122040. Epub 2022 Sep 11.
Ibirogba ER, Shazly SA, Chmait RH, Ruano R Is there a role for fetoscopic laser ablation therapy in Type-2 vasa previa? Ultrasound Obstet Gynecol. 2019 Nov;54(5):696. doi: 10.1002/uog.20251. No abstract available.
Jain V, Gagnon R Guideline No. 439: Diagnosis and Management of Vasa Previa. J Obstet Gynaecol Can. 2023 Jul;45(7):506-518. doi: 10.1016/j.jogc.2023.05.009. Epub 2023 May 18.
Klahr R, Fox NS, Zafman K, Hill MB, Connolly CT, Rebarber A Frequency of spontaneous resolution of vasa previa with advancing gestational age. Am J Obstet Gynecol. 2019 Dec;221(6):646.e1-646.e7. doi: 10.1016/j.ajog.2019.06.040. Epub 2019 Jun 21.
Langer O, Sonnendecker EW Characteristics and management of intrapartum prolonged fetal bradycardia. Br J Obstet Gynaecol. 1982 Nov;89(11):904-12. doi: 10.1111/j.1471-0528.1982.tb05055.x.
Monson MA, Chmait RH, Einerson B Fetoscopic Laser Ablation of Type II Vasa Previa: A Cost Benefit Analysis. Am J Perinatol. 2023 Jul 21. doi: 10.1055/s-0043-1771262. Online ahead of print.
Noble KG, Fifer WP, Rauh VA, Nomura Y, Andrews HF Academic achievement varies with gestational age among children born at term. Pediatrics. 2012 Aug;130(2):e257-64. doi: 10.1542/peds.2011-2157. Epub 2012 Jul 2.
Oyelese KO, Turner M, Lees C, Campbell S Vasa previa: an avoidable obstetric tragedy. Obstet Gynecol Surv. 1999 Feb;54(2):138-45. doi: 10.1097/00006254-199902000-00024.
Oyelese Y, Smulian JC Placenta previa, placenta accreta, and vasa previa. Obstet Gynecol. 2006 Apr;107(4):927-41. doi: 10.1097/01.AOG.0000207559.15715.98.
Oyelese Y Prenatally Diagnosed Vasa Previa: A Single-Institution Series of 96 Cases. Obstet Gynecol. 2017 Mar;129(3):581-582. doi: 10.1097/AOG.0000000000001919. No abstract available.
Oyelese Y Re: Incidence of and risk factors for vasa praevia: a systematic review: Vasa praevia screening. BJOG. 2017 Jan;124(1):162. doi: 10.1111/1471-0528.14013. No abstract available.
Society for Maternal-Fetal Medicine (SMFM) Electronic address: pubs@smfm.org; Martins JG, Biggio JR, Abuhamad A. Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline Number 3, April 2012). Am J Obstet Gynecol. 2020 Oct;223(4):B2-B17. doi: 10.1016/j.ajog.2020.05.010. Epub 2020 May 12.
Sorensen A, Peters D, Frund E, Lingman G, Christiansen O, Uldbjerg N Changes in human placental oxygenation during maternal hyperoxia estimated by blood oxygen level-dependent magnetic resonance imaging (BOLD MRI). Ultrasound Obstet Gynecol. 2013 Sep;42(3):310-4. doi: 10.1002/uog.12395.
Thurlow JA, Kinsella SM Intrauterine resuscitation: active management of fetal distress. Int J Obstet Anesth. 2002 Apr;11(2):105-16. doi: 10.1054/ijoa.2001.0933.
Tita AT, Andrews WW Diagnosis and management of clinical chorioamnionitis. Clin Perinatol. 2010 Jun;37(2):339-54. doi: 10.1016/j.clp.2010.02.003.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.